The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. 4D Molecular Therapeutics Inc shares valued at $8,165 were sold by Bizily Scott on Sep 16 ’24. At $16.33 per share, Bizily Scott sold 500 shares. The insider’s holdings dropped to 6,781 shares worth approximately $58723.46 following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Bizily Scott sold 500 shares, netting a total of over 7,500 in proceeds. Following the sale of shares at $15.00 each, the insider now holds 6,781 shares.
Before that, Bizily Scott had sold 1,750 shares from its account. In a trade valued at $47,442, the Chief Legal Officer traded 4D Molecular Therapeutics Inc shares for $27.11 each. Upon closing the transaction, the insider’s holdings decreased to 1,750 shares, worth approximately $58723.46.
As published in a research note from Cantor Fitzgerald on September 23, 2024, 4D Molecular Therapeutics Inc [FDMT] has been rated down from an Overweight to a Neutral. Analysts at Barclays started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid April. As of April 15, 2024, Barclays has initiated its “an Overweight” rating for FDMT.
Analyzing FDMT Stock Performance
During the last five days, there has been a drop of approximately -3.78%. Over the course of the year, 4D Molecular Therapeutics Inc shares have dropped approximately -57.26%. Shares of the company reached a 52-week high of $36.25 on 03/27/24 and a 52-week low of $8.53 on 10/10/24. A 50-day SMA is recorded $13.27, while a 200-day SMA reached $21.56. Nevertheless, trading volume fell to 0.51 million shares from 0.33 million shares the previous day.
Support And Resistance Levels for 4D Molecular Therapeutics Inc (FDMT)
According to the 24-hour chart, there is a support level at 8.49, which, if violated, would cause prices to drop to 8.31. In the upper region, resistance lies at 8.97. The next price resistance is at 9.27. RSI (Relative Strength Index) is 23.65 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.77, which suggests the price will decrease in the coming days. Percent R is at 95.13%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
